Moderna Reports Q2 Loss, Norovirus Vaccine Failure, and $950M Litigation Settlement
MRNA has more than doubled off its 52-week low of $22.28.
Summary
Moderna reported a Q2 net loss of $782 million, with its norovirus vaccine failing a Phase 3 interim analysis, and a $950 million litigation settlement impacting year-to-date results, despite positive regulatory updates for other vaccines.
Key Events · Earnings and Guidance · MRNA
-
Q2 Financial Results & YTD Loss
Moderna reported a Q2 2026 net loss of $782 million ($1.97 per share) on $145 million in revenue. Year-to-date, the net loss was $2.125 billion ($5.36 per share) on $534 million in revenue, largely due to a litigation settlement.
-
Norovirus Vaccine Phase 3 Failure
The Phase 3 study for mRNA-1403 (norovirus vaccine) did not meet statistical criteria for early success at its interim analysis. The trial is ongoing.
-
Significant Litigation Settlement Payment
A $950 million lump sum payment for a patent litigation settlement with Arbutus and Genevant was accrued in Q2 2026 and paid in July 2026, significantly impacting year-to-date cost of sales.
-
Positive Regulatory Progress for Other Vaccines
mCOMBRIAX (flu + COVID combination vaccine) received EU marketing authorization in April 2026. mRNA-1010 (seasonal flu vaccine) received a unanimous positive recommendation from an FDA advisory committee in June 2026, with a PDUFA date of August 5, 2026.
Analysis · MRNA · Life Sciences
This 10-Q provides the full financial details behind the Q2 earnings and norovirus vaccine news already announced via an 8-K on the same day. The significant net loss for the quarter and year-to-date is largely driven by a $950 million patent litigation settlement. The failure of the norovirus vaccine in its Phase 3 interim analysis is a notable clinical setback. However, the company also reported positive regulatory progress for its flu and flu+COVID combination vaccines, and demonstrated cost discipline with reduced R&D and SG&A expenses. Despite a decrease in cash and investments, the company maintains it has sufficient liquidity for at least the next 12 months. The insider 10b5-1 plans are primarily for managing expiring options and tax obligations, with President Hoge's plan involving a more substantial sale of exercised shares.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 29.4% of the 1563 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MRNA was trading at $54.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21.8B. The 52-week trading range was $22.28 to $85.60. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.